ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the usage of its “at the market” equity offering plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti might issue as well as market from time to time its common shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being offered at prevailing market prices averaging US$1.0747 a share. No securities were offered throughout the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with more freedom in its ongoing review process to explore as well as evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescribed drugs making use of OM3 fatty acids delivered both as totally free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for people with serious HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that aren’t statements of historical or current fact constitute “forward looking information” within the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, as well as other unknown elements that may result in the particular outcomes of Acasti to be materially different from historical success and as a result of any later outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are actually urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this press release. Forward-looking claims in that press release include, but are not confined to, info or statements concerning Acasti’s strategy, future operations as well as the review of its of strategic alternatives.
The forward-looking claims found in this press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area contained in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor aisle of Acasti’s site at www.acastipharma.com. All forward-looking statements in that press release are made as of the particular date of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward looking statements whether as a direct result of info that is brand new , future events or otherwise, except as required by law. The forward-looking assertions contained herein are also subject typically to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage